+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Uveitis - Epidemiology Forecast to 2029

  • ID: 5357278
  • Report
  • June 2021
  • Region: Global
  • 43 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Uveitis is a condition characterized by the inflammation of the uveal tract (iris, ciliary body, and choroid), but can also cause the inflammation of nearby tissues, such as the retina, the optic nerve, and the vitreous humor. Uveitis can affect one or both eyes. It primarily affects people ages 20-60 years, but can present at any age (National Eye Institute, 2019; Medscape, 2020). Uveitis is an important cause of blindness and visual loss in many communities (Wakefield and Chang, 2005). In most cases, the etiology remains elusive and is often of an autoimmune nature. In instances where the etiology is known, infectious agents or trauma are important causes.

The report includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of uveitis segmented by sex and age (ages ≥18 years). The diagnosed prevalent cases of uveitis are further segmented into anatomical site of inflammation (anterior, intermediate, posterior, and panuveitis), then by etiology (infectious, non-infectious, and idiopathic), severity (mild and moderate, and severe), and laterality (unilateral and bilateral). The following data describes epidemiology of uveitis. In the 9MM, the publisher epidemiologists forecast an increase in the diagnosed incident cases of uveitis in adults from 719,115 cases in 2019 to 780,725 cases in 2029, at an AGR of 0.86%. The diagnosed prevalent cases of uveitis in adults in the 9MM are expected to increase from 1,687,303 cases in 2019 to 1,851,766 cases in 2029, at an AGR of 0.97%. Women accounted for more diagnosed incident and diagnosed prevalent cases of uveitis than men in the 9MM and it predominantly affects older adults. These findings are in line with the publisher's estimates.

Scope
  • The Uveitis Epidemiology Report provides an overview of the risk factors and global trends of uveitis in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Australia, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of uveitis segmented by sex and age (ages ≥18 years). The diagnosed prevalent cases of uveitis are further segmented into anatomical site of inflammation (anterior, intermediate, posterior, and panuveitis), then by etiology (infectious, non-infectious, and idiopathic), severity (mild and moderate, and severe), and laterality (unilateral and bilateral). The model associated with this report additionally provides diagnosed incident cases of uveitis segmented into anatomical site of inflammation, etiology, course of disease (acute, recurrent, and chronic), and severity.
  • The uveitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
Reasons to Buy

The Uveitis Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global uveitis market.
  • Quantify patient populations in the global uveitis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for uveitis therapeutics in each of the markets covered.
  • Understand magnitude of uveitis population by anatomical site of inflammation, etiology, course of disease, severity, and laterality.
Note: Product cover images may vary from those shown
1 Uveitis: Executive Summary
1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports

2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 9MM Forecast Methodology
2.4.1 Sources
2.4.2 Forecast Assumptions and Methods
2.4.3 Forecast Assumptions and Methods: Diagnosed Incident and Diagnosed Prevalent Cases of Uveitis - 9MM
2.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation
2.4.5 Diagnosed Prevalent Cases of Uveitis by Etiology
2.4.6 Diagnosed Prevalent Cases of Uveitis by Severity
2.4.7 Diagnosed Prevalent Cases of Uveitis by Laterality
2.5 Epidemiological Forecast for Uveitis
2.5.1 Diagnosed Incident Cases of Uveitis
2.5.2 Age-Specific Diagnosed Incident Cases of Uveitis
2.5.3 Sex-Specific Diagnosed Incident Cases of Uveitis
2.5.4 Diagnosed Prevalent Cases of Uveitis
2.5.5 Age-Specific Diagnosed Prevalent Cases of Uveitis
2.5.6 Sex-Specific Diagnosed Prevalent Cases of Uveitis
2.5.7 Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Etiology, and Severity
2.5.8 Diagnosed Prevalent Cases of Uveitis by Laterality
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 COVID-19 Impact
2.6.3 Limitations of Analysis
2.6.4 Strengths of the Analysis

3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
3.3 Contact the Publisher

List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for Uveitis
Table 4: Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Etiology, and Severity
Table 5: Diagnosed Prevalent Cases of Uveitis by Laterality

List of Figures
Figure 1: 9MM, Diagnosed Incident Cases of Uveitis, Both Sexes, N, Ages ≥18 Years, 2019 and 2029
Figure 2: 9MM, Diagnosed Prevalent Cases of Uveitis, Both Sexes, N, Ages ≥18 Years, 2019 and 2029
Figure 3: 9MM, Diagnosed Incidence of Uveitis, Men and Women, Cases Per 100,000 Population, Ages ≥18 Years, 2019
Figure 4: 9MM, Diagnosed Prevalence of Uveitis, Men and Women, %, Ages ≥18 Years, 2019
Figure 5: 9MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of Uveitis
Figure 6: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation
Figure 7: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Etiology
Figure 8: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Severity
Figure 9: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Laterality
Figure 10: 9MM, Diagnosed Incident Cases of Uveitis, N, Both Sexes, Ages ≥18 Years, 2019
Figure 11: 9MM, Diagnosed Incident Cases of Uveitis by Age, N, Both Sexes, 2019
Figure 12: 9MM, Diagnosed Incident Cases of Uveitis by Sex, N, Ages ≥18 Years, 2019
Figure 13: 9MM, Diagnosed Prevalent Cases of Uveitis, N, Both Sexes, Ages ≥18 Years, 2019
Figure 14: 9MM, Diagnosed Prevalent Cases of Uveitis by Age, N, Both Sexes, 2019
Figure 15: 9MM, Diagnosed Prevalent Cases of Uveitis by Sex, N, Ages ≥18 Years, 2019
Note: Product cover images may vary from those shown
Adroll
adroll